Strata Skin Sciences Inc Stock Price, News & Analysis

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced preliminary first-quarter 2023 revenue estimates between $7.3 million and $7.8 million, marking the strongest results for the period since 2016. The company successfully placed 44 TheraClear®X devices, contributing to over 3,000 treatments sold since the product's launch in January 2023. Moreover, STRATA has converted 86 Pharos® accounts to XTRAC® devices, enhancing its presence in the eczema-laser market. CEO Bob Moccia expressed optimism about the sales momentum and its anticipated impact on revenues for 2023. The unaudited results are subject to revision, with full financial results expected in May 2023.

STRATA Skin Sciences, a medical technology firm, reported a record revenue of $36.2 million for 2022, up 21% from 2021, with fourth-quarter revenue at $10.6 million (17% increase year-over-year). Global recurring revenue reached $23 million for the year. Despite these gains, the company posted a net loss of $5.5 million for 2022 compared to a $2.7 million loss in 2021. The installed base of XTRAC® devices rose to 909. Looking forward, STRATA projects revenue in 2023 to be between $38 million and $40 million. The company aims to grow its market share while launching new marketing initiatives.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology firm focused on dermatologic treatments, will release its fourth-quarter 2022 financial results and Form 10-K on March 31, 2023. The company will hold a conference call at 8:30 AM EDT on the same day to discuss financial results and provide a corporate update. Key products include the XTRAC® and Pharos® excimer lasers, VTRAC® lamp systems, and the new TheraClear® X Acne Therapy System. STRATA operates a unique Partnership Program whereby practices are charged per treatment rather than for equipment purchases, ensuring support and marketing assistance.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced it will release its fourth quarter 2022 financial results on March 28, 2023, at 4:30 PM EDT. A conference call will be conducted to discuss the results and provide a corporate update. Interested parties can join the call using the numbers provided or view the webcast. STRATA specializes in products for treating dermatologic conditions such as psoriasis and acne.

STRATA Skin Sciences (NASDAQ: SSKN) has confirmed it has no financial ties or exposure to Silicon Valley Bank, stating that it does not hold cash deposits or securities with the bank. The company is focused on developing and marketing innovative dermatologic treatment technologies, including the XTRAC^® and Pharos^® lasers, as well as the TheraClear_®X Acne Therapy System. STRATA utilizes a Partnership Program to provide in-office treatment options, emphasizing a service-oriented approach over traditional equipment purchases.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced the launch of a new XTRAC® website on March 2, 2023. The site aims to enhance patient education about XTRAC excimer laser therapy for conditions like psoriasis and eczema. Key features include a Practice Finder tool, patient testimonials, and a Savings Program. CEO Bob Moccia emphasized the goal of increasing product awareness and improving patient access to treatment. The XTRAC device allows for targeted UVB light therapy, catering to a diverse patient base.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced on February 27, 2023, that it has regained compliance with Nasdaq's minimum bid price requirements under Rule 5550(a)(2). CEO Robert Moccia expressed optimism about the company's future growth prospects following this compliance notification. STRATA focuses on innovative products for dermatologic treatments, including the XTRAC and Pharos excimer lasers and the TheraClear X Acne Therapy System, employing a unique Partnership Program to facilitate treatment access. The company highlights its ongoing commitment to expand its product offerings and market presence.

HORSHAM, Pa., Feb. 16, 2023 - STRATA Skin Sciences (NASDAQ: SSKN) announced Dr. Joel L. Cohen will demonstrate the TheraClear®X device for acne treatment at the Winter Clinical Conference in Miami from February 17-20, 2023. The TheraClearX, FDA-cleared for mild to moderate acne, combines vacuum technology and intense broadband light to deliver results after just two treatments, with a recommended 4-6 sessions for optimal outcomes. STRATA's partnership program provides practices with a fee per treatment cost structure, including training and marketing support. Forward-looking statements about the product and market strategies highlight potential uncertainties affecting performance.

STRATA Skin Sciences (NASDAQ: SSKN) announced preliminary revenue for 2022 between $35-$36 million, a 17-19% increase from $30 million in 2021, exceeding previous guidance of $33-$35 million. The company attributed this growth to enhanced XTRAC® usage, refurbishing underutilized devices, and expanding international sales. CEO Bob Moccia expressed optimism about maintaining this growth momentum into 2023. These figures are unaudited and could be revised before the full financial results, expected in March 2023.